Ultragenyx Pharmaceutical (RARE) EBIAT (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed EBIAT for 10 consecutive years, with -$128.6 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 3.49% to -$128.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$575.0 million through Dec 2025, down 1.05% year-over-year, with the annual reading at -$575.0 million for FY2025, 1.05% down from the prior year.
- EBIAT for Q4 2025 was -$128.6 million at Ultragenyx Pharmaceutical, up from -$180.4 million in the prior quarter.
- The five-year high for EBIAT was -$73.0 million in Q3 2021, with the low at -$245.1 million in Q3 2022.
- Average EBIAT over 5 years is -$145.6 million, with a median of -$143.6 million recorded in 2021.
- The sharpest move saw EBIAT plummeted 583.62% in 2021, then surged 34.87% in 2023.
- Over 5 years, EBIAT stood at -$122.5 million in 2021, then decreased by 23.99% to -$151.8 million in 2022, then rose by 18.63% to -$123.6 million in 2023, then dropped by 7.81% to -$133.2 million in 2024, then rose by 3.49% to -$128.6 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$128.6 million, -$180.4 million, and -$115.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.